What are the signs and symptoms of Acanthosis nigricans, particularly in patients with insulin resistance and obesity?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 30, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Acanthosis Nigricans: Signs and Symptoms

Primary Clinical Presentation

Acanthosis nigricans presents as dark, thickened, velvety patches of skin with a papillomatous texture, most characteristically appearing in body folds and flexural areas. 1

Specific Physical Findings

Skin Characteristics

  • Hyperpigmented, velvety plaques with brownish-black coloration and hyperkeratotic texture 1, 2
  • Soft, velvet-like appearance with fine folding and papillae formation, creating an irregular surface 3
  • Thickening of the keratin layer giving an apparent darkening effect beyond simple pigmentation 4

Distribution Pattern

  • Neck (posterior and lateral) - most common and easily visible location 4, 5
  • Axillae (armpits) - classic presentation site 4, 3
  • Groin and inguinal folds 1
  • Beneath breasts in women 6
  • Vulvar area 6
  • Less commonly: knuckles, elbows, knees (acral distribution) 2

Associated Clinical Features in Insulin Resistance

Metabolic Signs

  • Obesity - present in majority of cases, particularly with abdominal fat distribution 7, 1
  • Hyperinsulinemia - the primary underlying pathophysiologic driver 4, 5
  • Insulin resistance - impaired cellular response to insulin with compensatory hypersecretion 1, 4

Endocrine Manifestations in Women

  • Virilization with male-pattern features 7
  • Hirsutism (excessive hair growth) 7
  • Acne 8
  • Enlarged, cystic ovaries suggesting polycystic ovary syndrome 7
  • Clitoromegaly in severe cases 8, 6

Cardiovascular Risk Markers

  • Hypertension - frequently coexists with insulin resistance 7
  • Dyslipidemia - abnormal cholesterol and triglyceride levels 7

Critical Diagnostic Considerations

Timing and Progression

Acanthosis nigricans appears long before glucose intolerance develops, serving as an early warning sign for type 2 diabetes risk 4. In children and adolescents, it functions as an early marker for insulin resistance, often preceding diabetes by years 8, 9, 6.

Malignancy-Associated Features (Red Flags)

  • Rapid progression of skin changes 9
  • "Tripe palms" - palmar involvement with ridged, velvety texture 9, 6
  • Extensive distribution beyond typical flexural areas 6
  • Most commonly associated with gastric adenocarcinoma when malignancy-related 9, 6

Pediatric Presentation

In children, fasting plasma insulin concentrations correlate most significantly with acanthosis nigricans presence 5. Children with acanthosis nigricans demonstrate significantly more glucose intolerance and insulin resistance compared to those without the skin finding, even when matched for age and obesity level 5.

Common Pitfalls to Avoid

Misdiagnosis Risk

Do not dismiss acanthosis nigricans as simply a cosmetic concern or normal variant in obese patients - it represents a reliable cutaneous marker of underlying metabolic dysfunction requiring systematic evaluation 4, 5.

Type 1 vs Type 2 Diabetes Confusion

In pediatric patients with acanthosis nigricans and new-onset diabetes, distinguishing type 1 from type 2 can be challenging, as diabetes-associated autoantibodies and ketosis may be present even in patients with obesity and acanthosis nigricans 9, 6.

Screening Gaps

Acanthosis nigricans warrants immediate screening for insulin resistance, diabetes, dyslipidemia, and hypertension - not just observation 6. The presence of this skin finding indicates the patient has already progressed beyond simple obesity into metabolic dysfunction 7.

References

Research

A Comprehensive Review of Acanthosis Nigricans: Pathogenesis, Clinical manifestation and Management.

Recent advances in inflammation & allergy drug discovery, 2025

Research

Acral Acanthosis Nigricans in a Case of Scleroderma.

Indian journal of dermatology, 2015

Research

Acanthosis nigricans is a reliable cutaneous marker of insulin resistance in obese Japanese children.

Pediatrics international : official journal of the Japan Pediatric Society, 2003

Guideline

Diagnostic Approach for Acanthosis Nigricans and Buffalo Hump

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Management of Acanthosis Nigricans

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Acanthosis Nigricans in Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the differential diagnosis and what questions should be asked in the history for a 13-year-old female presenting with black or dark patches on her neck in a dermatology clinic?
What is the pathophysiology of acanthosis nigricans at the molecular, functional, and anatomical levels?
What is the treatment for acanthosis nigricans in individuals with diabetes?
What is the cause of skin darkening in Diabetes Mellitus (DM)?
What is the best treatment approach for a patient with acanthosis nigricans, potentially related to underlying liver disease or malnutrition, and impaired renal function (indicated by low creatinine levels)?
What are the potential causes of pancreatic pain radiating to the back?
What is the management approach for a patient with Takayasu arteritis (TA), history of old cerebrovascular accident (CVA), metabolic acidosis, acute kidney injury (AKI), hyperkalemia, and elevated troponin levels, with a C-reactive protein (CRP) level of 291 and potential rhabdomyolysis?
What is the role of azathioprine in treating autoimmune and inflammatory skin conditions in dermatology?
Can we try R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) after a patient with non-Hodgkin lymphoma has undergone a polar CHP (cyclophosphamide, doxorubicin, prednisone) chemotherapy regimen?
What is the mechanism of action and potential adverse effects of Vincristine (Oncovin)?
What is the best salvage therapy option for a patient with relapsed or refractory non-Hodgkin lymphoma (NHL) who has undergone a polar CHP (cyclophosphamide, hydroxydaunorubicin, and prednisone) chemotherapy regimen, between R-DHAP (rituximab, dexamethasone, cisplatin, and cytarabine), R-ICE (rituximab, ifosfamide, carboplatin, and etoposide), and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.